Usage and dosage of evantumumab/carestream

Amivantamab is administered by intravenous injection, and the dosage and regimen usually need to be individually adjusted based on the patient's weight and combined treatment regimen. As a new type of targeted drug, its usage and dosage are designed to take into account drug exposure levels and tolerance, ensuring that it can achieve effective anti-tumor effects while minimizing the risk of adverse reactions.

When used alone or in combination with Lazertinib to treat non-small cell lung cancer (NSCLC), the recommended regimen is once weekly for five weeks. The initial treatment phase requires dividing the dose over two days to reduce the incidence of infusion-related reactions. From the seventh week, the treatment frequency is adjusted to once every two weeks to maintain stable blood drug concentration. In terms of specific dosage, 1050 mg is recommended for patients weighing less than 80 kg, and 1400 mg for patients weighing 80 kg or more. Such a stratified design can ensure that people of different weights receive relatively balanced drug effects.

In the chemotherapy regimen combining carboplatin and pemetrexed, the dosing cycle of evantumumab is more complicated. During the first four weeks of treatment, the drug was injected once a week, again divided into two days of dosing in the first week. After entering the seventh week, the dosing frequency was adjusted to once every three weeks, in conjunction with the chemotherapy cycle. The dose is still divided based on body weight: The starting dose for patients under 80 kg is 1,400 mg, and is increased to 1,750 mg after the seventh week; while for patients weighing 80 kg or more, the starting dose is 1,750 mg, and is increased to 2,100 mg after the seventh week.

This phased and weight-based medication strategy not only reflects the metabolic characteristics of antibody drugs in the body, but also reflects the comprehensive clinical consideration of patient safety and compliance. For long-term treatment, standardized dosing regimens can significantly improve the stability of efficacy and reduce adverse events caused by improper dosage.

Reference materials:https://www.rybrevant.com/